BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22748660)

  • 1. Passive immunotherapeutic strategies for the treatment of malignant gliomas.
    Nagasawa DT; Fong C; Yew A; Spasic M; Garcia HM; Kruse CA; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):481-95. PubMed ID: 22748660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for glioma: promises and challenges.
    Han SJ; Zygourakis C; Lim M; Parsa AT
    Neurosurg Clin N Am; 2012 Jul; 23(3):357-70. PubMed ID: 22748649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials with immunotherapy for high-grade glioma.
    Ruzevick J; Jackson C; Phallen J; Lim M
    Neurosurg Clin N Am; 2012 Jul; 23(3):459-70. PubMed ID: 22748658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of cellular immunotherapy for patients with glioblastoma.
    Vauleon E; Avril T; Collet B; Mosser J; Quillien V
    Clin Dev Immunol; 2010; 2010():. PubMed ID: 20953324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy for malignant glioblastoma].
    Nose T; Nakagawa K
    No Shinkei Geka; 1995 Mar; 23(3):195-206. PubMed ID: 7700486
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical immunotherapy for brain tumors.
    Fecci PE; Sampson JH
    Neuroimaging Clin N Am; 2002 Nov; 12(4):641-64. PubMed ID: 12687917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Armed hunter killers: discerning the role of adoptive T-cell transfer for glioblastoma.
    Samaha H; El Naggar S; Ahmed N
    Immunotherapy; 2015; 7(5):481-5. PubMed ID: 26065474
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor-Specific T Cell Activation in Malignant Brain Tumors.
    Mohme M; Neidert MC
    Front Immunol; 2020; 11():205. PubMed ID: 32117316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
    Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
    Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
    Holladay FP; Heitz T; Wood GW
    J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive cell transfer therapy for malignant gliomas.
    Ishikawa E; Takano S; Ohno T; Tsuboi K
    Adv Exp Med Biol; 2012; 746():109-20. PubMed ID: 22639163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
    Genoud V; Migliorini D
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
    Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
    Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.
    Mitra S; Li G; Harsh GR
    Neurosurg Clin N Am; 2010 Jan; 21(1):67-76. PubMed ID: 19944967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.
    Ryu JI; Han MH; Cheong JH; Kim JM; Kim CH
    Immunotherapy; 2017 Mar; 9(5):411-421. PubMed ID: 28357913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
    Munari L; Silvani A; Passerini CG; Radrizzani M; Parmiani G; Boiardi A
    J Neurosurg Sci; 1990; 34(3-4):283-8. PubMed ID: 1965907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvilli expressed on glioma cells keep cytotoxic cells at a distance.
    Zaguia F; Schneider R
    Cancer Biol Ther; 2011 Jan; 11(1):1-3. PubMed ID: 21189451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immunotherapy for malignant gliomas.
    Lin Y; Okada H
    Expert Opin Biol Ther; 2016 Oct; 16(10):1265-75. PubMed ID: 27434205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for the treatment of glioblastoma.
    Thomas AA; Ernstoff MS; Fadul CE
    Cancer J; 2012; 18(1):59-68. PubMed ID: 22290259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.